Analysis of Profitability Ratios
Quarterly Data
Profitability ratios measure the company ability to generate profitable sales from its resources (assets).
Paying user area
Try for free
Abiomed Inc. pages available for free this week:
- Cash Flow Statement
- Common-Size Balance Sheet: Assets
- Analysis of Liquidity Ratios
- Analysis of Solvency Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Enterprise Value to EBITDA (EV/EBITDA)
- Enterprise Value to FCFF (EV/FCFF)
- Price to Book Value (P/BV) since 2005
- Analysis of Revenues
- Analysis of Debt
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Abiomed Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Profitability Ratios (Summary)
Abiomed Inc., profitability ratios (quarterly data)
Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-K (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-K (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-K (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-K (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-K (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-K (reporting date: 2017-03-31), 10-Q (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30).
- Gross Profit Margin
- The gross profit margin remains relatively stable over the observed periods, consistently staying above 80%. Starting at 84.14% in late 2016, it experiences a slight downward trend through 2020, reaching around 80.8%. From late 2020 to late 2022, the margin stabilizes in the range of approximately 81 to 81.5%, indicating maintained efficiency in production costs relative to sales.
- Operating Profit Margin
- The operating profit margin shows an overall upward trend from mid-2016 reaching a peak around early 2020 near 30.5%. After this peak, there is a notable decline during 2021, falling to approximately 13.6% by mid-2022. This indicates a phase of stronger operational profitability that weakened significantly in the later period under review.
- Net Profit Margin
- The net profit margin increases steadily from around 11.7% in mid-2016 to a high of approximately 33.7% in early 2019, indicating improving overall profitability. Following this peak, there is a considerable fluctuation and general decline, dipping to around 13.2% by early 2022. A recovery trend is observed by late 2022, with margins rebounding to near 24.8%, suggesting volatility but potential stabilization in profitability.
- Return on Equity (ROE)
- ROE exhibits a similar pattern, rising from approximately 11.5% in mid-2016 to a high above 27% in early 2019. After this period, ROE declines steadily, hitting lows below 10% in early 2022. The late 2022 figures indicate a recovery trend back towards around 17%, signaling fluctuations in shareholder returns but an improving outlook towards the end of the period.
- Return on Assets (ROA)
- The ROA increases from around 9.5% in mid-2016 to a peak in the range of 24.5% in early 2019, reflecting efficient asset utilization during this time. Subsequently, ROA decreases substantially through 2021 to a low near 8%, before showing signs of recovery and rising to nearly 15.7% by late 2022. This trajectory parallels the patterns observed in ROE and net profit margin, emphasizing cyclicality in overall asset efficiency and profitability.
Return on Sales
Return on Investment
Gross Profit Margin
Abiomed Inc., gross profit margin calculation (quarterly data)
| Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||||||
| Gross profit | ||||||||||||||||||||||||||||||||||
| Revenue | ||||||||||||||||||||||||||||||||||
| Profitability Ratio | ||||||||||||||||||||||||||||||||||
| Gross profit margin1 | ||||||||||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||||||||||
| Gross Profit Margin, Competitors2 | ||||||||||||||||||||||||||||||||||
| Abbott Laboratories | ||||||||||||||||||||||||||||||||||
| Elevance Health Inc. | ||||||||||||||||||||||||||||||||||
| Intuitive Surgical Inc. | ||||||||||||||||||||||||||||||||||
| Medtronic PLC | ||||||||||||||||||||||||||||||||||
| UnitedHealth Group Inc. | ||||||||||||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-K (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-K (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-K (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-K (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-K (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-K (reporting date: 2017-03-31), 10-Q (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30).
1 Q2 2023 Calculation
Gross profit margin = 100
× (Gross profitQ2 2023
+ Gross profitQ1 2023
+ Gross profitQ4 2022
+ Gross profitQ3 2022)
÷ (RevenueQ2 2023
+ RevenueQ1 2023
+ RevenueQ4 2022
+ RevenueQ3 2022)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The financial data reveals several key trends in the company's performance over the observed periods. Revenue exhibited a general upward trajectory from June 2016 through June 2022, with fluctuations including periods of accelerated growth as well as temporary declines.
- Revenue Analysis
- Starting at approximately $103 million in mid-2016, revenue increased steadily, achieving a peak of about $277 million in December 2021. Notably, there were some periods of decline, particularly from March 2020 to June 2020, where revenue decreased from $206.7 million to $164.9 million, likely reflecting external challenges during that period. Subsequent quarters showed recovery and continued growth, although some volatility persisted near the end of the dataset.
- Gross Profit Trends
- Gross profit followed a broadly positive trend alongside revenue growth. Beginning around $88 million in mid-2016, gross profit reached its highest levels in the latter part of the time frame, peaking close to $224 million in mid-2022. However, the gross profit dipped notably in mid-2020, coinciding with the decrease in revenue. Despite such dips, gross profit generally maintained a close correlation with revenue movements, indicating stable cost structures.
- Gross Profit Margin Insights
- The gross profit margin showed relative stability throughout the periods, fluctuating within a narrow range just above 80%. Initially not reported for the early periods, the margin from late 2016 onward ranged mostly between 80.8% and 84.1%. There was a slight declining trend in the margin over time, with earlier peaks above 83% gradually tapering to levels nearer 81% by 2022. This suggests some modest compression in profitability relative to revenue, potentially due to increased costs or pricing pressures.
Overall, the company exhibited strong revenue expansion and gross profit growth over multiple years, despite some volatility linked to external factors around 2020. The gross profit margin's relative consistency indicates effective cost management, though a subtle erosion in margin percentage merits attention for future operational efficiency. These trends highlight the company's resilience and capacity for growth, while also underscoring areas for continued focus on maintaining profitability ratios.
Operating Profit Margin
Abiomed Inc., operating profit margin calculation (quarterly data)
| Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||||||
| Income (loss) from operations | ||||||||||||||||||||||||||||||||||
| Revenue | ||||||||||||||||||||||||||||||||||
| Profitability Ratio | ||||||||||||||||||||||||||||||||||
| Operating profit margin1 | ||||||||||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||||||||||
| Operating Profit Margin, Competitors2 | ||||||||||||||||||||||||||||||||||
| Abbott Laboratories | ||||||||||||||||||||||||||||||||||
| Elevance Health Inc. | ||||||||||||||||||||||||||||||||||
| Intuitive Surgical Inc. | ||||||||||||||||||||||||||||||||||
| Medtronic PLC | ||||||||||||||||||||||||||||||||||
| UnitedHealth Group Inc. | ||||||||||||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-K (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-K (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-K (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-K (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-K (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-K (reporting date: 2017-03-31), 10-Q (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30).
1 Q2 2023 Calculation
Operating profit margin = 100
× (Income (loss) from operationsQ2 2023
+ Income (loss) from operationsQ1 2023
+ Income (loss) from operationsQ4 2022
+ Income (loss) from operationsQ3 2022)
÷ (RevenueQ2 2023
+ RevenueQ1 2023
+ RevenueQ4 2022
+ RevenueQ3 2022)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
- Revenue Trends
- Over the observed periods, revenue demonstrated a consistent upward trajectory from mid-2016 through early 2022, increasing from approximately 103 million US dollars in June 2016 to a peak near 277 million US dollars by June 2022. This growth reflects steady expansion with occasional periods of stabilization, notably around mid-2019 to early 2020 and again showing a slight decline in mid to late 2022.
- Income (loss) from Operations Trends
- Income from operations generally followed revenue growth, rising from about 21 million US dollars in June 2016 to a high over 70 million US dollars by late 2020. However, there was a significant disruption in mid-2021 when a notable loss of approximately 49 million US dollars was recorded. Following this anomaly, operating income quickly recovered and returned to positive figures, reaching close to 66 million US dollars by mid-2022.
- Operating Profit Margin Analysis
- Operating profit margins, available from late 2016, showed a consistent improvement from around 20% to over 30% by the end of 2019, indicating increased operational efficiency or cost management. In 2020 and early 2021, margins slightly declined but remained above 27%, illustrating resilient profitability despite fluctuating income levels. The significant loss recorded in mid-2021 corresponded with a sharp reduction in margin to approximately 15%, followed by a further dip around 14% in late 2021 and mid-2022. By late 2022, margins rebounded to the mid-20% range, signaling a partial recovery in operational profitability.
- Notable Insights
- The data indicates a generally positive growth trend in revenue and operating income over the period, with a pronounced exception during mid-2021 when operational losses occurred. Despite these losses, the firm's ability to regain positive income and improve margins toward the end of the period demonstrates underlying resilience. The margin expansion from 2016 through 2019 suggests effective scaling, while the subsequent volatility may reflect market or internal challenges impacting operational efficiency temporarily.
Net Profit Margin
Abiomed Inc., net profit margin calculation (quarterly data)
| Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||||||
| Net income (loss) | ||||||||||||||||||||||||||||||||||
| Revenue | ||||||||||||||||||||||||||||||||||
| Profitability Ratio | ||||||||||||||||||||||||||||||||||
| Net profit margin1 | ||||||||||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||||||||||
| Net Profit Margin, Competitors2 | ||||||||||||||||||||||||||||||||||
| Abbott Laboratories | ||||||||||||||||||||||||||||||||||
| Elevance Health Inc. | ||||||||||||||||||||||||||||||||||
| Intuitive Surgical Inc. | ||||||||||||||||||||||||||||||||||
| Medtronic PLC | ||||||||||||||||||||||||||||||||||
| UnitedHealth Group Inc. | ||||||||||||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-K (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-K (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-K (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-K (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-K (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-K (reporting date: 2017-03-31), 10-Q (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30).
1 Q2 2023 Calculation
Net profit margin = 100
× (Net income (loss)Q2 2023
+ Net income (loss)Q1 2023
+ Net income (loss)Q4 2022
+ Net income (loss)Q3 2022)
÷ (RevenueQ2 2023
+ RevenueQ1 2023
+ RevenueQ4 2022
+ RevenueQ3 2022)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The financial data reflects several notable trends in the company's performance over the observed periods.
- Net Income (Loss)
- Net income exhibits significant fluctuations across quarters. Starting with moderate values in 2016, net income increased substantially by mid-2017, reaching a peak in June 2018. This peak is followed by notable quarterly volatility, including a pronounced loss in June 2021, which represents a clear deviation from the otherwise positive earnings trend. Subsequently, net income rebounds strongly with marked increases toward the end of 2022, culminating in the highest value observed in the dataset for September 2022.
- Revenue
- Revenue shows a generally positive upward trend throughout the period. The company experienced steady growth from 2016 through early 2019, with occasional minor dips. In mid-2020, a notable decrease is observed, which may relate to broader economic or industry conditions during that timeframe. Despite this, revenue recovered and continued to grow, surpassing previous highs with consistent strength through 2021 and into 2022, reaching peak values within the last few quarters recorded.
- Net Profit Margin
- The net profit margin demonstrates improvement from mid-2017 onward, with values generally increasing and peaking between 2018 and early 2019. Margins remain relatively high through 2019, followed by some volatility. A noticeable dip in profitability is evident in 2021, aligning with the quarter where net income experienced a loss. Profit margins rebound throughout 2022, suggesting a recovery in both profitability and operational efficiency. Margins in late 2022 approach levels close to those seen during the earlier peak periods.
Overall, the company shows a pattern of strong growth in revenue complemented by corresponding increases in net income and profit margins during most periods. However, financial performance displays episodic volatility, particularly with losses and margin contractions during 2021. The recovery in subsequent quarters indicates resilience and improved profitability heading into late 2022. This analysis highlights both growth potential and the necessity for monitoring factors behind income fluctuations to sustain long-term financial health.
Return on Equity (ROE)
Abiomed Inc., ROE calculation (quarterly data)
| Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||||||
| Net income (loss) | ||||||||||||||||||||||||||||||||||
| Stockholders’ equity | ||||||||||||||||||||||||||||||||||
| Profitability Ratio | ||||||||||||||||||||||||||||||||||
| ROE1 | ||||||||||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||||||||||
| ROE, Competitors2 | ||||||||||||||||||||||||||||||||||
| Abbott Laboratories | ||||||||||||||||||||||||||||||||||
| Elevance Health Inc. | ||||||||||||||||||||||||||||||||||
| Intuitive Surgical Inc. | ||||||||||||||||||||||||||||||||||
| Medtronic PLC | ||||||||||||||||||||||||||||||||||
| UnitedHealth Group Inc. | ||||||||||||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-K (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-K (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-K (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-K (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-K (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-K (reporting date: 2017-03-31), 10-Q (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30).
1 Q2 2023 Calculation
ROE = 100
× (Net income (loss)Q2 2023
+ Net income (loss)Q1 2023
+ Net income (loss)Q4 2022
+ Net income (loss)Q3 2022)
÷ Stockholders’ equity
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
The analysis of the quarterly financial data reveals distinct trends in net income, stockholders’ equity, and return on equity (ROE) over the examined periods.
- Net Income (Loss)
- Net income has demonstrated significant variability across the quarters. Starting at a positive 12,910 thousand US dollars on June 30, 2016, it experienced fluctuations with notable peaks such as 90,066 thousand in June 30, 2018, and 106,133 thousand in September 30, 2022. Some quarters, however, showed decreased profitability, including a loss indicated by a negative figure of -26,525 thousand on June 30, 2021. Overall, despite periodic declines and losses, the net income trend reveals strong recovery and growth phases, indicating cyclical variations in profitability but generally increasing earnings towards the later periods.
- Stockholders’ Equity
- Stockholders’ equity exhibited a consistent growth trajectory throughout the periods. Beginning at 377,327 thousand US dollars in June 30, 2016, the figure rose steadily, reaching over 1.5 million thousand US dollars by September 30, 2022. This continuous increase reflects an expanding capital base, accumulation of retained earnings, or additional capital contributions, underlining the company’s strengthening financial position and accumulated value for shareholders.
- Return on Equity (ROE)
- ROE figures start being reported from March 31, 2017, with an initial value of 11.53%. The ratio increased notably to a peak of 27.65% on December 31, 2018, signifying efficient use of shareholders’ equity to generate profits during this period. Post this peak, a downward trend is observed, dipping to the single digits around March 31, 2022 (9.28%) and June 30, 2022 (9.08%). However, a recovery phase follows, with ROE rising again to 17.32% by September 30, 2022. This pattern suggests fluctuating profitability relative to equity, with periods of strong earnings efficiency followed by some deceleration and later improvement.
In summary, the financial data reflects a company with robust and growing equity base, significant fluctuations in net income indicative of operational and market variability, and an initially strong but variable ROE that signals changes in profitability efficiency over time. These trends collectively indicate dynamic financial performance with periods of growth and challenge, ultimately showing resilience and improvement towards the latest quarters observed.
Return on Assets (ROA)
Abiomed Inc., ROA calculation (quarterly data)
| Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||||||
| Net income (loss) | ||||||||||||||||||||||||||||||||||
| Total assets | ||||||||||||||||||||||||||||||||||
| Profitability Ratio | ||||||||||||||||||||||||||||||||||
| ROA1 | ||||||||||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||||||||||
| ROA, Competitors2 | ||||||||||||||||||||||||||||||||||
| Abbott Laboratories | ||||||||||||||||||||||||||||||||||
| Elevance Health Inc. | ||||||||||||||||||||||||||||||||||
| Intuitive Surgical Inc. | ||||||||||||||||||||||||||||||||||
| Medtronic PLC | ||||||||||||||||||||||||||||||||||
| UnitedHealth Group Inc. | ||||||||||||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-K (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-K (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-K (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-K (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-K (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-K (reporting date: 2017-03-31), 10-Q (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30).
1 Q2 2023 Calculation
ROA = 100
× (Net income (loss)Q2 2023
+ Net income (loss)Q1 2023
+ Net income (loss)Q4 2022
+ Net income (loss)Q3 2022)
÷ Total assets
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
- Net income (loss)
- Over the observed period, net income demonstrated significant volatility. Initial values showed moderate income with a peak at 90,066 thousand US dollars in June 2018, followed by fluctuations around that range. A notable decline occurred in the period ending June 2021, where net income turned negative, recording a loss of 26,525 thousand US dollars. However, this loss was followed by a quick recovery with net income rising again, reaching a record high of 106,133 thousand US dollars by September 2022. Overall, the trend suggests periodic fluctuations with an underlying tendency toward growth in net income over the long term.
- Total assets
- Total assets exhibited a consistent upward trend throughout the timeframe. Starting from 429,312 thousand US dollars in mid-2016, assets grew steadily to peak at over 1,703,544 thousand US dollars by September 2022. This growth was continuous, reflecting ongoing asset accumulation without significant retrenchment at any point. This steady asset increase may indicate company expansion, investment in resources, or acquisitions within the period.
- Return on Assets (ROA)
- ROA data, available from March 2017 onwards, initially showed an improving trend from 9.47% to a peak of 24.57% in March 2019, indicating enhanced profitability relative to asset base during this period. Following this peak, there was a gradual decline to values near 8.16% by June 2022, with some minor fluctuations. Despite the later decline, ROA remained positive throughout, indicating the company maintained profitability on its assets. The decline in ROA could suggest rising asset base outpacing income growth or reduced operational efficiency in recent periods.
- Summary
- The company experienced growth in both net income and total assets over the analysis period, albeit with notable fluctuations in profitability and income. While asset growth was steady and consistent, net income showed volatility including a significant loss within one quarter, followed by recovery to all-time highs. ROA peaked in early 2019 signaling strong asset profitability then gradually decreased, possibly indicating diminishing returns on expanded asset base or economic challenges towards the end of the period. Overall, the data suggests expansion accompanied by periods of operational and financial variability.